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Nuclear factor of activated T cells 5 (NFAT5) is a transcription factor
involved in the regulation of several genes involved in the response to
extracellular hyperosmolality. Recently, the uptake of ibuprofen by an as
yet unknown carrier was suggested in Madin-Darby canine kidney
(MDCK) I cells exposed to hyperosmolality. We therefore speculated that
Nfat5 could be involved in the regulation of this ibuprofen carrier. Reverse
transfection with siRNA against Nfat5 was used to knock down Nfat5 in
MDCK I cells. The uptake of both radiolabelled taurine and ibuprofen
was measured in MDCK I cells, first treated with siRNA against Nfat5
and afterwards cultivated with raffinose-supplemented normal growth med-
ium (500 mOsm) for 24 h. The siRNA transfection resulted in knockdown
of Nfat5, and uptake of both taurine and ibuprofen was significantly
decreased in transfected MDCK I cells. The decrease in ibuprofen uptake
indicates that Nfat5 is involved in upregulation of the ibuprofen carrier. A
transcriptome analysis of MDCK I cells treated with siRNA against Nfat5
revealed 989 genes upregulated by Nfat5 during hyperosmotic exposure.
From these genes, the gene product transmembrane protein 184b was
found to be regulated by Nfat5, and Tmem184b was the only potential
gene product involved in the uptake of ibuprofen in MDCK I cells.
Dataset
The RNA sequencing dataset is available from the NCBI Gene Expression
452 Omnibus (https://www.ncbi.nlm.nih.gov/geo/) with the accession num-
ber GSE122074.
Nuclear factor of activated T cells 5 (NFAT5), also
referred to as tonicity-responsive binding-protein
(TonEBP), is a major transcriptional factor in the cel-
lular response to hyperosmolality [1]. Several genes are
affected by NFAT5 during hyperosmotic exposure [2].
BGT1 (SLC6A12), SMIT1 (SLC5A3), TauT (SLC6A6)
and aldose reductase (AKR1B1) are particularly
important genes regulated by NFAT5 [3–6]. The pro-
teins of the mentioned genes protect the cell during
hyperosmolality by accumulating uncharged small
organic osmolytes intracellularly. This process is vital,
because the osmolytes can be accumulated in high
Abbreviations
MDCK, Madin-Darby canine kidney; NFAT5, nuclear factor of activated T cells 5; SLC, solute carrier; Tmem184b, transmembrane protein
184b; TonEBP, tonicity-responsive binding-protein.
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concentrations with little effect on other cellular pro-
cesses [7]. Recently, an ibuprofen carrier was detected
functionally in Madin-Darby canine kidney (MDCK) I
cells after exposure to hyperosmolality [8]. The protein
or proteins responsible for the cellular uptake of
ibuprofen have not yet been identified. However, the
upregulation of the underlying protein appears to be a
result of increased transcription since the transcription
inhibitor, actinomycin D, and the translation inhibitor,
cycloheximide, both inhibit the upregulation of cellular
ibuprofen accumulation [9].
A transcriptome analysis of MDCK I cells during
hyperosmotic exposure has recently provided an over-
view of transporting proteins regulated by hyperosmo-
lality [10]. From this analysis, 25 candidate solute
carriers (SLCs) were selected, and a siRNA knockdown
approach was attempted without any effect on the
hyperosmotic-induced ibuprofen uptake in MDCK I
cells (unpublished data). Therefore, further information
about the regulatory signal upregulating ibuprofen
uptake is needed in order to provide experimental tools
to identify the underlying gene responsible for the
ibuprofen transport in MDCK I cells. As several SLCs,
such as SLC6A6, SLC5A3 and SLC6A12, are regulated
by NFAT5 during hyperosmolality, we hypothesize
that this transcription factor could also be involved in
the upregulation of the ibuprofen carrier. Knowing the
involvement of Nfat5 in the regulation of the ibuprofen
transport will provide a possible new experimental
approach to a new transcriptome analysis. This would
potentially lower the number of candidates for the
ibuprofen carrier. The aim of the present study is there-
fore to first investigate if a siRNA-mediated knock-
down of Nfat5 in MDCK I cells affects the uptake of
ibuprofen during hyperosmolality. And secondly, the
aim is to use the obtained knowledge to perform a full
transcriptome analysis aimed at identifying putative
candidate genes coding for a carrier for ibuprofen. The
findings of the study identified a set of 989 genes regu-
lated by Nfat5 during hyperosmolality, and among
these, transmembrane protein 184bB (Tmem184b) was
investigated further. The upregulation of Tmem184b
during hyperosmolality and the likely involvement of
Nfat5 in the regulation improve the knowledge about
the function and regulation of Tmem184b and suggest
a role of the protein in ibuprofen transport.
Materials and methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM)/F-12, Tween
20, phosphate-buffered saline solution, penicillin–streptomycin,
siRNA constructs, d-(+)-raffinose pentahydrate, RIPA buf-
fer, 2-mercaptoethanol, 4-(2-hydroxyethyl)-1-piperazineetha-
nesulphonic acid (HEPES), Triton X-100, Trypsin–EDTA
(910) and L-glutamine were all purchased from Sigma-
Aldrich (St. Louis, MO, USA). Hank’s balanced saline solu-
tion (HBSS) (109) and sodium bicarbonate (7.5%) were
obtained from Gibco, Invitrogen (Paisley, UK). RS-[3H(G)]
ibuprofen ([3H]-ibuprofen; 20 Cimmol1) was from Ameri-
can Radiolabelled Chemicals, Inc. (St. Louis, MO, USA).
[2,2-3H(N)]-taurine ([3H]-taurine; 10.1 Cimmol1) and
Ultima Gold scintillation liquid were purchased from Perki-
nElmer (Boston, MA, USA). Cell culture plastic ware was
obtained from Corning Life Science (Wilkes Barre, PA,
USA). Water was obtained from a Milli-Q water purification
system (Merck Millipore, Darmstadt, Germany). FBS,
PierceTM BCA protein assay kit and Lipofectamine RNAi-
MAX were from Thermo Fisher Scientific (Waltham, MA,
USA). cOmpleteTM ULTRA Tablets, Mini, EASYpack Pro-
tease Inhibitor Cocktail were purchased from Roche Diag-
nostics (Mannheim, Germany). Four to twenty percent
Mini-PROTEAN TGX Stain-FreeTM Protein Gels, Trans-
Blot TurboTM Mini poly(vinylidene difluoride) (PVDF)
Transfer packs, 109 Tris-glycine-SDS buffer, 109 Tris-buf-
fered saline, blotting-grade blocker, Precision ProteinTM
StrepTactin-HRP Conjugate, Precision plus proteinTM
WesternCTM protein standard, 49 Laemmli sample buffer
and goat anti-rabbit IgG (H + L)-HRP Conjugate were
obtained from Bio-Rad (Hercules, CA, USA). Polyclonal
rabbit anti-Nfat5 antibody was from Novus biological.
Cell cultivation
Madin-Darby canine kidney I cells were obtained from
European Collection of Authenticated Cell Cultures
(ECACC, Porton Down, UK) and cultured using DMEM/
F-12 containing 1% penicillin–streptomycin, 2 mM
L-glutamine and 10% FBS (normal growth medium) in an
atmosphere of 5% CO2- 95% O2 at 37 °C.
siRNA knockdown
Madin-Darby canine kidney I cells were transfected with
siRNA by reverse transfection against Nfat5 or Tmem184b.
Briefly, siRNA (100 nM final concentration) and 1.5 lL
Lipofectamine RNAiMAX in a total volume of 100 lL
serum-free medium were prepared following the protocol of
the manufacture and added to each well (24-well plate, well
area 1.9 cm2) and incubated at room temperature for
approximately 20 min. Then, 400 lL cell suspension with a
concentration of 427 500 MDCK I cells per mL (90 000
MDCK I cells per cm2) in normal growth medium was
added. The cells were incubated at 37 °C 5% CO2 over-
night. The next day, the medium containing siRNA was
removed and exchange with normal growth medium over-
night, whereafter raffinose-supplemented (200 mOsm)
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normal growth medium (total osmolality of 500 mOsm)
was added for 24 h. To control cells, Slc22a6-siRNA
(Neg-siRNA) was used with cells treated with normal
growth medium (300 mOsm) and raffinose-supplemented
normal growth medium (500 mOsm), as Slc22a6 is not
expressed in MDCK I cells [10]. After 24 h, the cellular
uptake of either [3H]-ibuprofen (50 nM, 1 lCimL1) 1 or
[3H]-taurine (99 nM, 1 lCimL1) was measured. When
transfecting with siRNA against Tmem184b, the medium
was not changed the day after transfection. Instead, the
cells were treated with raffinose-supplemented growth med-
ium (500 mOsm) for 24 h resulting in a total cultivation
time of 48 h. The sequences of the siRNA constructed used
for siRNA transfection are given in Table 1.
Cellular uptake of ibuprofen and taurine
Before the uptake studies, the cells were equilibrated in
prewarmed HBSS containing 10 mM HEPES and adjusted
to pH 7.4 at 37 °C for 15 min. The cells were then incu-
bated for 5 min at 37 °C with [3H]-ibuprofen (50 nM,
1 lCimL1) 1 or [3H]-taurine (99 nM, 1 lCimL1) in
HBSS with 10 mM HEPES adjusted to pH 7.4 using 1 mM
NaOH. After incubation, the uptake medium was removed
and the cells were washed three times with ice-cold HBSS.
The cells were detached by addition of 200 lL 0.1% Triton
X-100 in Milli-Q water. The cell suspension was transferred
to pony vials, and 2 mL of Ultima Gold scintillation fluid
was added followed by liquid scintillation counting using
a TriCarp 4910 TR liquid scintillation counter from
PerkinElmer.
Western blotting
Total protein from MDCK I cells was isolated by wash-
ing the cells with ice-cold PBS and afterwards treating
with 109 RIPA buffer containing 19 protease inhibitor.
The total protein content was measured using PierceTM
BCA protein assay following the protocol of the manufac-
ture. Protein samples for western blotting were prepared
by heating the protein to 95 °C for 5 min and adding 49
Laemmli sample buffer and 2-mercaptoethanol to a final
concentration of 1 mgmL1 protein, 19 Laemmli sample
buffer and 1 : 39 2-mercaptoethanol. The samples were
loaded to a precast 4–20% polyacrylamide Stain-FreeTM
gel and ran using 200 V in 19 Tris-glycine-SDS buffer.
Precision plus proteinTM WesternCTM protein standard was
used as protein ladder. After running, the gel was acti-
vated in a ChemiDocTM XRS+ imager (Bio-Rad) and then
blotted to a PVDF blot using trans-blot turboTM blotter
(Bio-Rad). The blot was then treated with a 5% blocking
solution (milk) in 19 TBST and then with primary anti-
body (1 : 1000) in a 5% blocking 19 TBST solution over-
night at 4 °C on a rocker. The next day, secondary
antibody (1 : 3000) was added in 5% milk in 19 TBST
containing Precision ProteinTM StrepTactin-HRP Conjugate
(1 : 5000). Following the treatment with secondary anti-
body, the HRP substrate was added to the blot and then
visualized. The software Imager LabTM (Bio-Rad) was used
to calculate the relative loaded protein and the relative
band intensity.
Real-time PCR
Total RNA was isolated using Nucleospin RNA/Protein
(Macherey-Nagel GmbH Co., D€uren, Germany) following
the protocol of the manufacture. cDNA was obtained by
using High Capacity cDNA Reverse Transcription Kit, and
Power SYBR Green PCR Master Mix (Applied Biosys-
tem, Foster City, CA, USA) was used for real-time PCR,
following the respective protocols. All reactions were run in
duplicates. Primers (PentaBase, Odense, Denmark) were
used at a concentration of 450 nM. The sequence of the
primers used was as follows: Nfat5 forward: ACCCAGA
Table 1. siRNA constructed used in siRNA knockdown.
Accession number Gene target Nr Direction Sequence
XM_533258.5 Slc22a6 (Neg) – Sense (50–30) CCAAUGGCUGGAUCUACGA
Antisense (50–30) UCGUAGAUCCAGCCAUUGG
XM_005620767.3 Nfat5 1 Sense (50–30) GAATAATGGTACTCAGCAA
Antisense (50–30) UUGCUGAGUACCAUUAUUC
XM_005620767.3 Nfat5 2 Sense (50–30) CUCACAUGAUGAGUGCAUU
Antisense (50–30) AAUGCACUCAUCAUGUGAG
XM_005620767.3 Nfat5 3 Sense (50–30) CUUCUAAUCAGCUGCCCAA
Antisense (50–30) UUGGGCAGCUGAUUAGAAG
XM_005625888.3 Tmem184b 1 Sense (50–30) GCAAGUACCGGGAUGGUGA
Antisense (50–30) UCACCAUCCCGGUACUUGC
XM_005625888.3 Tmem184b 2 Sense (50–30) GCCUUCACCUACAAAGUCU
Antisense (50–30) AGACUUUGUAGGUGAAGGC
XM_005625888.3 Tmem184b 3 Sense (50–30) CCAUCGAGUCCAGCUGUAU
Antisense (50–30) AUACAGCUGGACUCGAUGG
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GACCCTGACAACT, Nfat5 reverse: TGAAACTGGGTA
GCCTGCTG, Tmem184b forward: GTGGAGATGTTCTT
CGCAGC, Tmem184b reverse: GCCATACGTCGGCACT
TG, Gapdh forward: GGAGGGCCTCATGACCACCGT
and Gapdh reverse: CACATCTTCCCAGAGGGGCCGT.
RNA sequencing
Madin-Darby canine kidney I cells treated with siRNA and
cultivated in isosmotic (300 mOsm) and hyperosmotic (raf-
finose; 500 mOsm) culture medium were used for RNA
sequencing. RNA was isolated from the MDCK I cells
using Nucleospin RNA/Protein (Macherey-Nagel GmbH
Co.). The purity of the RNA was measured with a frag-
ment analyser (AATI), following the protocol of the manu-
facturer. The library preparation was performed using
NEBNext Ultra II RNA Library Prep Kit for Illumina
(NEB), and the protocol of the manufacturer was followed.
The sequencing was performed using a NovaSeq6000 (S2
flow cell) with paired end and a read length of 51. The
quality of the sequence was evaluated using fastQC. The
samples were mapped using Hisat 2.05 against the Canis
familiaris 3.1 genome, received from Ensembl (http://www.e
nsembl.org/index.html). Each sample was counted using
featureCounts with the 92 annotation of Canis familiaris
3.1. DESeq2 was used to perform the statistical analysis
[11]. All the samples were used to estimate the size factor
and the dispersion. Genes, where the sum of counts was
below five in all eight samples, were excluded. The contrast
function in DESeq2 was then used to compare the individ-
ual conditions. An adjusted P-value of 0.05 was used to
determine whether a gene was differentially expressed in a
condition. To adjust the P-value for the false discovery
rate, the Benjamini–Hochberg–Yekutieli method was used.
The R-package ‘pheatmap’ was used to create the heatmap
of the RNA-sequence analysis.
Statistical analysis
All samples were performed in atleast biological triplicates,
except the RNA sequencing that was performed in biologi-
cal duplicates. Data are represented as mean  SEM. Sam-
ples were compared by one-way ANOVA, and Dunnet’s
multiple comparison test was used to determine the levels
of statistical significance, where a P-value < 0.05 was con-
sidered significant.
Results
siRNA knockdown of Nfat5 in MDCK I cells
The expression of Nfat5 was knocked down in MDCK
I cells using a siRNA approach. The effect of the
knockdown at the protein level was investigated by
western blotting (see Fig. 1A,B,C) and at the mRNA
level by real-time PCR (see Fig. 2).
Fig. 1. Protein expression of Nfat5 in Nfat5-siRNA-treated MDCK I
cells cultivated under hyperosmotic conditions. (A) The protein
expression of NFAT5, (B) total protein loading control and C: the
relative band intensity of Nfat5 in MDCK I cells treated with lane 1:
Neg-siRNA (300 mOsm), lane 2: Neg-siRNA (500 mOsm), lane 3:
Nfat5-1-siRNA (500 mOsm), lane 4: Nfat5-2-siRNA (500 mOsm)
and lane 5: Nfat5-3-siRNA (500 mOsm). The protein was separated
on a 4–20% polyacrylamide Stain-FreeTM gel and immunoblotted
using anti-Nfat5 (1 : 1000). (A) The immunoblot represents an
illustrative example of the results from three different cell
passages, n = 3. (B) The total protein blot represents an illustrative
example of the results from three different experiments, n = 3. (C)
The band intensity was normalized to the total protein loaded using
Imager LabTM software. Each column represents the mean  SEM
of three different cell passages (n = 3). One-way ANOVA followed
by Dunnet’s multiple comparison test was used to determine the
levels of statistical significance (*P < 0.05).
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As seen in Fig. 1A, the protein expression of Nfat5
was visually similar in the raffinose and the isosmotic
treated cells. However, all three siRNA-Nfat5 resulted
in a decrease in the protein level of Nfat5, compared to
the raffinose-treated MDCK I cells. The amount of
loaded protein in each well was determined using stain-
free precast gels and was similar in all wells (see
Fig. 1B). The relative band intensity of Nfat5 (see
Fig. 1C) showed that the Nfat5 expression was 3.3 times
lower in Nfat5-siRNA (500 mOsm)-treated MDCK I
cells compared to the Neg-siRNA (500 mOsm). There
was no significant change in the relative band intensity
of Nfat5 Neg-siRNA (500 mOsm) compared to Neg-
siRNA (300 mOsm).
There was no significant difference in the mRNA
level of Nfat5, 72 h after transfection with each of the
three Nfat5 siRNAs. The level of Nfat5 was 3.1 times
higher in the hyperosmotic (500 mOsm)-treated MDCK
I cells, compared to the isosmotic (300 mOsm)-treated
cells, and the difference was statistically significant
(P value = 0.002).
siRNA-mediated silencing of Nfat5 expression
attenuates uptake of taurine and ibuprofen in
hyperosmotic-treated MDCK I cells
The uptake of radiolabelled taurine and ibuprofen
in MDCK I cells, treated with three different Nfat5-
siRNAs and raffinose, was investigated (see Fig. 3).
The results depicted in Fig. 3 show that the uptake
of taurine and ibuprofen in raffinose- and Neg-
siRNA-treated MDCK I cells was increased, compared
to the cells cultivated under isosmotic conditions. Fur-
thermore, the uptake of taurine and ibuprofen was
decreased in MDCK I cells treated with any of the
three Nfat5-siRNAs (500 mOsm), compared to
MDCK I cells treated with Neg-siRNA (500 mOsm),
respectively, thus confirming the involvement of Nfat5
in the hyperosmotic upregulation of both taurine and
ibuprofen transport.
Transcriptome analysis of Nfat5-siRNA-treated
MDCK I cell under hyperosmotic conditions
A transcriptome analysis of Nfat5-siRNA-treated
MDCK I cells under hyperosmotic conditions was per-
formed to identify possible candidates for the responsi-
ble gene of the ibuprofen carrier. A total of 989 genes
were significantly (P-adjusted < 0.05) upregulated by
hyperosmolality (500 mOSm) compared to the
isosmotic condition (300 mOsm) and simultaneously sig-
nificantly decreased (P-adjusted < 0.05) by both Nfat5-
siRNA (construct 1 and 2) treatments (500 mOsm)
compared to the hyperosmotic condition (500 mOsm).
Of the 989 genes, the top 50 regulated genes are shown as
a heatmap in Fig. 4. A complete list of the 989 genes is
found in Table S1.
A hierarchical cluster analysis of the transcriptomes
(data not shown) showed a similar cluster tree as the
one in the heatmap (see Fig. 4).
Notably, the SLCs Slc6a6, Slc6a12 and Slc5a3 as well
as the enzyme Akr1b1 had a significant (P-
adjusted < 0.05) involvement of Nfat5 in the upregula-
tion during hyperosmolality. These findings are
important because Nfat5 regulates Slc6a6, Slc6a12,
Slc5a3 and Akr1b1 during hyperosmolality. mRNA
expression ofNfat5 was significantly (P-adjusted < 0.05)
upregulated 3.5 times by hyperosmolality (500 mOsm)
compared to the isosmotic condition (300 mOsm), but
the Nfat5-siRNA showed no effect on the Nfat5 mRNA
level compared to the hyperosmotic (500 mOsm) condi-
tion.
The 989 potentially Nfat5 regulated genes were com-
pared to the Pfam protein families database [12], and
this revealed that Tmem184b is in the Pfam protein
Fig. 2. Relative mRNA expression of Nfat5 in Nfat5-siRNA-treated
MDCK I cells cultivated under hyperosmotic conditions. MDCK 1
cells were treated with (100 nM) Neg-siRNA (300 mOsm), Neg-
siRNA (500 mOsm), Nfat5-1-siRNA (500 mOsm), Nfat5-2-siRNA
(500 mOsm) and Nfat5-3-siRNA (500 mOsm) using raffinose-
supplemented growth medium as hyperosmotic condition. The
MDCK I cells were exposed to hyperosmolality 48 h after the
siRNA treatment and the hyperosmotic exposure lasted 24 h. The
relative RNA level of Nfat5 was measured by real-time PCR and
normalized by the expression of Gapdh. Each column represents
the mean  SEM of three different cell passages (n = 3). One-way
ANOVA followed by Dunnet’s multiple comparison test was used
to determine the levels of statistical significance (*P < 0.05).
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family Solute_trans_a (PF03619). The Solute_trans_a
family is the family of the organic solute transporter
subunit alpha (Ostalpha).
Nfat5 is involved in the regulation of Tmem184b
during hyperosmotic exposure
A validation of the association between Nfat5 and
Tmem184b was performed by real-time PCR (see
Fig. 5).
The real-time PCR analysis of the Tmem184b
expression showed that there was a significant 6.7
times upregulation of Tmem184b, when MDCK I cells
were exposed to hyperosmolality (500 mOsm) com-
pared to the isosmotic condition (300 mOsm). Further-
more, the transfection of MDCK I cells with all three
Nfat5-siRNAs resulted in a 2.3 times lower Tmem184b
expression compared to the hyperosmotic-treated
MDCK I cells treated with Neg-siRNA.
Tmem184b could be partly responsible for the
ibuprofen uptake in hyperosmotic-treated MDCK
I cells
The discovery that Tmem184b belongs to the
Solute_trans_a Pfam protein family led to the hypothesis
that Tmem184b can be involved in the hyperosmotic-
induced ibuprofen uptake either as a regulatory factor or
as the actual protein responsible for ibuprofen transport.
The mRNA level of Tmem184b during the hyperosmotic
exposure was knocked down using siRNA against
Tmem184b (see Fig. 6).
The real-time PCR analysis in Fig. 6 shows that the
knockdown of Tmem184b resulted in an average of 10
times lower mRNA expression of Tmem184b com-
pared to MDCK I cells treated with Neg-siRNA
(500 mOsm). Furthermore, the level of Tmem184b was
14 times higher in the hyperosmotic-treated MDCK I
cells compared to the isosmotic treated.
The ibuprofen uptake in Tmem184b-siRNA-trans-
fected MDCK I cells was measured after the exposure
of hyperosmolality for 24 h (see Fig. 7).
The ibuprofen uptake was 8.4 times higher in the
hyperosmotic (500 mOsm)-treated MDCK I cells com-
pared to the isosmotic (300 mOsm)-treated MDCK I
cells, when they were transfected with Neg-siRNA,
which was significantly different. Only Tmem184b-2-
siRNA resulted in a significant decrease of the ibupro-
fen uptake in hyperosmotic (500 mOsm)-treated
MDCK I cells. The two other Tmem184b-siRNA con-
structs had no significant effect on the ibuprofen
uptake.
Fig. 3. Cellular uptake of [3H]-ibuprofen and [3H]-taurine in Nfat5-siRNA-treated MDCK I cells cultivated under hyperosmotic conditions.
Cellular uptake rate of 1 lCimL1 [3H]-taurine (99 nM) (A) and 1 lCimL1 [3H]-ibuprofen (B) (50 nM) in MDCK I cells treated with (100 nM)
Neg-siRNA (300 mOsm), Neg-siRNA (500 mOsm), Nfat5-1-siRNA (500 mOsm), Nfat5-2-siRNA (500 mOsm) and Nfat5-3-siRNA (500 mOsm).
The MDCK I cells were exposed to hyperosmolality 48 h after the siRNA treatment and the hyperosmotic exposure lasted 24 h. HBSS
containing 10 mM HEPES adjusted to pH 7.4 with 1 mM NaOH was used as uptake buffer at 37°. The uptake was measured for 5 min.
Each column represents the mean  SEM of three to four different cell passages (n = 3–4). One-way ANOVA followed by Dunnet’s
multiple comparison test was used to determine the levels of statistical significance (*P < 0.05).
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Discussion
Nfat5 is involved in the upregulation of an
ibuprofen carrier in hyperosmotic-treated MDCK I
cells
The NFAT family consists of five proteins, that is
NFAT1 (NFATc2 or NFATp), NFAT2 (NFATc1 or
NFATc), NFAT3 (NFATc4), NFAT4 (NFATc3 or
NFATx) and NFAT5 (TonEBP or OREBP) [13],
whereof NFAT5 is important during hyperosmolality.
As a response to hyperosmolality, mammalian cells
upregulate the SLCs Slc6a6, Slc5a3 and Slc6a12 [14–16].
These carriers are, in part, responsible for the survival of
the cell during states of hyperosmolality by accumulating
uncharged small organic osmolytes. Nfat5 is the tran-
scription factor involved in the osmotic regulation of
Slc6a6, Slc5a3 and Slc6a12 [3,5,6]. During hyperosmolal-
ity, the level of NFAT5 in the nucleus increases. This is
caused by an upregulation of NFAT5 and a transloca-
tion of NFAT5 from the cytoplasm to the nucleus [17].
In the present study, we investigated whether NFAT5
was involved in the regulation of an ibuprofen carrier
functionally upregulated in MDCK I cells during hyper-
osmolality. A siRNA knockdown approach was used. A
previous study found the protein level of NFAT 5
decreased 2 and 3 days after transfection with siRNA
against NFAT5, whereas the level of NFAT5 was nor-
mal after 7 days [3]. Similarly, we found that the protein
level of Nfat5 decreased 3 days after transfection; how-
ever, the mRNA level was not significantly affected. The
contradiction of the decreased protein level and unaf-
fected mRNA may be because the effect of the siRNA
knockdown is starting to lose effectiveness, which would
Fig. 4. Heatmap of the top 50 genes
affected by Nfat5-siRNA and hyperosmotic
treatment. The presented genes are the
top 50 genes significantly (P-adjusted
< 0.05) upregulated by hyperosmolality
(500 mOsm) compared to the isosmotic
(300 mOsm) and simultaneously
significantly decreased (P-adjusted < 0.05)
by both Nfat5-siRNA treatments
(500 mOsm) compared to the
hyperosmotic condition (500 mOsm). The
colour of each cell represents the relative
expression of the gene in the specific
condition compared to the average
expression of all conditions. The genes are
ordered according to the P-adjust value of
upregulated genes from the hyperosmotic
condition (500 mOsm) compared to the
isosmotic condition (300 mOsm). The
statistical analysis was performed with
DESeq2, and the false discovery rate was
controlled by the Benjamini–Hochberg–
Yekutieli method with a significance level
of 0.05. n = 2 passages (each represented
in the figure). The heatmap was generated
using the R-package ‘Pheatmap’.
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first be seen at the mRNA level and later at the protein
level. The known Nfat5 regulated SLCs Slc6a6, Slc5a3
and Slc6a12 as well as the enzyme Akr1b1 were all found
downregulated in Nfat5-siRNA-transfected cells in the
transcriptome analysis. These results combined with
the decreased function of Slc6a6, seen by a decrease in
the taurine uptake, show that the Nfat5-siRNA-
transfection provided a system with loss of function of
Nfat5. The decreased ibuprofen uptake of siRNA-
Nfat5-transfected MDCK I cells, therefore indicated
that Nfat5 was involved in the upregulation of the
responsible gene after exposure to hyperosmotic condi-
tions. It could further indicate that the ibuprofen carrier
was somewhat involved in the cellular response to hyper-
osmolality in MDCK I cells due to the role of Nfat5
during hyperosmolality. However, to confirm this fur-
ther studies are needed.
Tmem184b could be involved in the increased
ibuprofen uptake in hyperosmotic-treated MDCK
I cells
Transporting proteins detected functionally, but with no
knowledge of the underlying gene responsible, have
traditionally been identified using expression cloning
[14,16,18–20]. We tried a similar approach to identify
the ibuprofen carrier, with enrichment of mRNA by
fractionation on a sucrose gradient and then expressed
in Xenopus laevis oocytes (data not shown). However,
the result showed no significant difference in the ibupro-
fen uptake in Xenopus laevis oocytes injected with the
fractions of mRNA from hyperosmotic-treated MDCK
I cells. One complicating factor for analysing data on
ibuprofen uptake in Xenopus laevis oocytes is that
ibuprofen had a high passive transport in this system.
Therefore, it was difficult to identify a low-capacity car-
rier such as the ibuprofen carrier [8]. A different
approach was therefore needed to identify possible can-
didates for the ibuprofen carrier. The ibuprofen carrier
is most likely upregulated transcriptionally [9]. A tran-
scriptome analysis of genes upregulated in hyperos-
motic-treated MDCK I cells should include the
underlying transcript responsible for the ibuprofen
uptake. Previously, we have identified the SLCs regu-
lated by hyperosmolality in MDCK I cells [10]. A
Fig. 5. Relative mRNA expression of Tmem184b in Nfat5-siRNA-
treated MDCK I cells cultivated under hyperosmotic conditions.
MDCK 1 cells were treated with (100 nM) Neg-siRNA (300 mOsm),
Neg-siRNA (500 mOsm), Nfat5-1-siRNA (500 mOsm), Nfat5-2-
siRNA (500 mOsm) and Nfat5-3-siRNA (500 mOsm). The MDCK I
cells were exposed to hyperosmolality 48 h after the siRNA
treatment and the hyperosmotic exposure lasted 24 h. The relative
RNA level of Tmem184b was measured by real-time PCR and
normalized by the expression of Gapdh. Each column represents
the mean  SEM of three different cell passages (n = 3). One-way
ANOVA followed by Dunnet’s multiple comparison test was used
to determine the levels of statistical significance (*P < 0.05).
Fig. 6. Relative mRNA expression of Tmem184b in Tmem184b-
siRNA-treated MDCK I cells cultivated under hyperosmotic
conditions. MDCK 1 cells were treated with (100 nM) Neg-siRNA
(300 mOsm), Neg-siRNA (500 mOsm), Tmem184b-1-siRNA
(500 mOsm), Tmem184b-2-siRNA (500 mOsm) and Tmem184b-3-
siRNA (500 mOsm). The MDCK I cells were exposed to
hyperosmolality 24 h after the siRNA treatment and the
hyperosmotic exposure lasted 24 h. The relative RNA level of
Tmem184b was measured by real-time PCR and normalized by the
expression of Gapdh. Each column represents the mean  SEM of
three different cell passages (n = 3). One-way ANOVA followed by
Dunnet’s multiple comparison test was used to determine the
levels of statistical significance (*P < 0.05).
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siRNA approach to knock down each of the identified
SLCs did not result in a potential candidate for the
ibuprofen carrier (data not shown). It was therefore
expected that the responsible gene was not currently
annotated as a SLC. With the additional knowledge of
the involvement of Nfat5 in the regulation of the
ibuprofen carrier, we performed a transcriptome analy-
sis to identify genes regulated by Nfat5 during hyperos-
molality in MDCK I cells. The set of Nfat5 regulated
genes was run against the Pfam protein family database
to identify whether they belonged to a SLC family. The
analysis revealed that, of the genes listed, Tmem184b is
part of the Solute_trans_a family (PF03619). Solute_-
trans_a is the family of organic solute transporter alpha
(SLC51A). SLC51A is the alpha subunit of the Ostalpha-
Ostbeta heterodimer carrier [20]. The Ostalpha-Ostbeta is
responsible for the basolateral bile acid and steroid
transport in the intestinal, renal and biliary epithelia
[21]. The physiological role of Tmem184b is still
unknown, but a few studies have investigated
Tmem184b [22,23]. TMEM184b is expressed in the ner-
vous system, and it was suggested present in the plasma
membrane and necessary for the maintenance of the
peripheral nerve terminal and its morphology in vivo
[22]. Another study found TMEM184b upregulated in
cancer, and that it is important for the migration and
invasion of cancer in vitro [23]. The family resembles
between Tmem184b and Slc51a could reveal that
Tmem184b might, in part, be involved for the ibuprofen
uptake in MDCK I cells exposed to hyperosmolality.
Further, resemblance between Ostalpha and the ibupro-
fen carrier is that they are both anion carriers and
sodium independent [8,24]. However, the uptake of
anionic ibuprofen in hyperosmotic-treated MDCK I
cells is saturable both at the apical and at basolateral
membrane, whereas Ostalpha-Ostbeta is a basolateral car-
rier [9]. As only one siRNA construct against
Tmem184b had an effect on the uptake of ibuprofen,
but all three knocked down the mRNA level of
Tmem184b, it was not possible to unequivocally deter-
mine whether Tmem184b is partly responsible for the
uptake of ibuprofen. The absent of attenuated ibupro-
fen uptake after treatment with two of the siRNA con-
structs against Tmem184b could possibly be explained
by a lack of change in phenotype despite a substantial
attenuation of the mRNA level of Tmem184b.
Tmem184b was also found upregulated 9.8 and 7.0 times
in a 12-replica transcriptome analysis of hyperosmotic-
treated MDCK I cell caused by both raffinose
(500 mOsm) and NaCl (500 mOsm), respectively, but
no effect was seen by urea confirming the transcription
osmotic regulation of Tmem184b [10].
Conclusions
The present study showed that Nfat5 is involved in the
regulation of the functional upregulation of ibuprofen
transport in MDCK I cells during hyperosmotic expo-
sure. By transcriptome analysis, a set of genes were
identified, which were regulated by Nfat5 during
hyperosmolality among these also Tmem184b. The
upregulation of Tmem184b during hyperosmolality
and the likely involvement of Nfat5 in the regulation
improve the knowledge regarding Tmem184b about its
function and regulation. The present study further sug-
gested that Tmem184b is partly involved in the uptake
of ibuprofen in hyperosmotic-treated MDCK I cells.
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Table S1. List of genes regulated by Nfat5 in hyperos-
motic-treated MDCK I cells during hyperosmolality.
The list includes the genes significantly (P-adjusted
< 0.05) upregulated by hyperosmolality (500 mOsm)
compared to the isosmotic (300 mOsm) medium and
simultaneously significantly decreased (P-adjusted
< 0.05) by both Nfat5-siRNA treatments (500 mOsm)
compared to the hyperosmotic condition (500 mOsm).
The statistical analysis was performed with DESeq2,
and the false discovery rate was controlled by the
Benjamini–Hochberg–Yekutieli method with a signifi-
cance level of 0.05. n = 2 passage.
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